1Vinayagamoorthy T, Zhang D, Ye F, Vinayagamoorthy D,
Hodkinson R (2017) Can detection of Braf p.V600E mutation
be improved? Comparison of allele specific multiplex sequencing
to present tests. Journal of Solid Tumors. 7:2.
2Mehnert JM and Kluger HM (2012) Driver Mutations in
Melanoma: Lessons Learned From Bench-to-Bedside Studies.
Curr Oncol Rep. 14: 449–457.
3Mellert H, Foreman T, Jackson L, et al. (2017) Development
and Clinical Utility of a Blood- Based Test Service for the Rapid
Identification of Actionable Mutations in Non–Small Cell
Lung Carcinoma. 19: 3 404–416.
4Yoruker EE, Holdenrieder S, Gezer U (2016) Blood-based
biomarkers for diagnosis, prognosisand treatment of colorectal
cancer. Clinica Chimica Acta. 455: 1 26-32.
5Moorthy T (2018) Targeted therapy: a potential oversight in
trial protocol. The Lancet Oncology. 19: 39.
6Prieto-Potin I, Montagut C, Bellosillo B, et al. (2018) Multicenter
Evaluation of the Idylla NRAS-BRAF Mutation Test in
Metastatic Colorectal Cancer. J Mol Diagn. 20 :664-676.
7Kevin Q, Qiulu P, Xi Z, et al. (2013) Detection of BRAF V600
Mutations in Metastatic Melanoma. Comparison of the Cobas
4800 and Sanger Sequencing Assays. The Journal of Molecular
Diagnostics. 15: 790.
8Moorthy T (2018) An algorithm to evaluate the efficacy of
detecting somatic mutations. Journal of Solid Tumors 8: 2.